MERCAPTOPURINE


Trade Names	MERCAPTOPURINE PURINETHOL PURIXAN
Synonyms	6-mercaptopurine 6-mercaptopurine monohydrate Mercaptopurine Mercaptopurine anhydrous Mercaptopurine hydrate Mercaptopurinum NSC-755 NSC-759614 Puri-nethol Purinethol Purixan Xaluprine
Status
Molecule Category	UNKNOWN
ATC	L01BB02
UNII	E7WED276I5


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WFFQYWAAEWLHJC-UHFFFAOYSA-N
Smiles	O.S=c1[nH]cnc2nc[nH]c12
InChI	InChI=1S/C5H4N4S.H2O/c10-5-3-4(7-1-6-3)8-2-9-5;/h1-2H,(H2,6,7,8,9,10);1H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C5H6N4OS
Molecular Weight	170.2
AlogP	0.64
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	0.0
Polar Surface Area	54.46
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	10.0

Pharmacology

Mechanism of Action	Action	Reference
Amidophosphoribosyltransferase inhibitor	INHIBITOR	PubMed DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Oxidoreductase	-	-	-	-	12-28
Enzyme Transferase	-	-	79433	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	105

Related Entries

--- ---

Cross References

Resources	Reference
ChEBI	31822
ChEMBL	CHEMBL1200751
DrugBank	DB01033
FDA SRS	E7WED276I5
Guide to Pharmacology	7226
KEGG	C01756
PubChem	2724350
SureChEMBL	SCHEMBL141410
ChEBI	94796
ChEMBL	CHEMBL1425
DrugBank	DB01033
DrugCentral	1708
FDA SRS	PKK6MUZ20G
Human Metabolome Database	HMDB0015167
Guide to Pharmacology	7226
KEGG	C02380
PDB	PM6
PharmGKB	PA450379
PubChem	2724350
SureChEMBL	SCHEMBL3893
ZINC	ZINC000004658290

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).